Plain-English translation of ·
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a large real-world study testing peginterferon alpha-2b, alone or combined with antiviral pills, for people with inactive chronic hepatitis B. Researchers want to see whether these treatment combinations can help achieve a 'functional cure'—meaning the virus becomes undetectable or you develop immunity to it. The study will follow participants for about three years to measure how well the different approaches work.
Most guidelines recommend that people with inactive hepatitis B don't need treatment and should just be monitored—but some patients are at risk of developing active disease or liver cancer over time, and many want treatment options. This medication has shown promise in preliminary studies, and doctors need real-world evidence to understand whether treating inactive patients now might prevent serious complications later.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of five treatment groups that test different combinations of medications. Some groups start with antiviral pills alone, then add the peginterferon medication; others use both from the start or use one medication alone. The maximum treatment period is 96 weeks (about 22 months), followed by an additional 144 weeks (about 3 years) of follow-up visits to monitor your response. You'll have regular blood tests and clinic visits to check your hepatitis B levels and watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China